Dr. Sanjeev Kumar Panchal
#292Managing Director
54
Age
26y
Exp
22y
Tenure
5/10
Risk
🎓 B.Sc. · Aligarh Muslim University
📜 PhD in Business Administration · Aligarh Muslim University
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
3
Neur
Astrazeneca Phar
Healthcare · Mid Cap
Mature Stable · Bureaucratic
About
Dr. Sanjeev Kumar Panchal is the Managing Director of Astrazeneca Phar, a Mid Cap company in the Healthcare sector with a market cap of ₹22K Cr. A Pragmatic leader with 26 years of experience, he is known for data-driven decision-making and organic builder strategy. Focuses on steady, science-led healthcare delivery and methodical expansion within the highly regulated Indian pharmaceutical market.
FAQ
What is Dr. Sanjeev Kumar Panchal's leadership style?
Dr. Sanjeev Kumar Panchal is classified as a Pragmatic leader. He is data-driven in decision-making, with a shareholder champion motivation and steady-marathon pace of execution.
What is Dr. Sanjeev Kumar Panchal's educational background?
Dr. Sanjeev Kumar Panchal holds a B.Sc. from Aligarh Muslim University and a PhD in Business Administration from Aligarh Muslim University.
Who is the CEO of Astrazeneca Phar?
Dr. Sanjeev Kumar Panchal is the Managing Director of Astrazeneca Phar. He has been with the company for 22 years and in the current role for 2 years.
Leadership DNA
ArchetypePragmatic
MotivationShareholder Champion
CrisisSteady Hand
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerSteady Employer
BrandTrusted
FocusOperational Excellence
OrientationDeep Specialist
Leadership Evidence
“Focuses on steady, science-led healthcare delivery and methodical expansion within the highly regulated Indian pharmaceutical market.”
⚡ Crisis●●●○○
As MD of AstraZeneca India, his strategy focuses on consistent execution of the company's global 'Ambition 2025' strategy rather than reactive restructuring.
🎯 Motivation●●●○○
His leadership is characterized by a strong focus on delivering consistent double-digit growth and value for the publicly listed AstraZeneca Pharma India entity.
👥 People●●●●○
His management style is defined by data-driven operational excellence and rigorous adherence to global compliance and performance benchmarks.
📈 Growth●●●●○
He has focused on expanding the company's footprint in specialty therapeutic areas like oncology and rare diseases through internal portfolio optimization.
💡 Innovation●●●●○
As the Indian subsidiary of a global MNC, it focuses on localizing and commercializing high-value patented global assets rather than early-stage R&D discovery.
🏃 Pace●●●●○
Operates with the methodical, process-driven rhythm typical of a global pharmaceutical multinational focused on long-term compliance and product lifecycle management.
🌱 Purpose●●●●○
The company maintains a strong ESG framework and active CSR programs centered on healthcare access and disease awareness, aligning with its global sustainability strategy.
🏷️ Brand●●●●○
Leverages the global reputation of the AstraZeneca brand for clinical excellence, safety, and scientific rigor in the medical community.
🤝 Customer●●●●●
Operates primarily through a complex B2B network of hospitals, specialized medical practitioners, and pharmaceutical distributors rather than direct-to-consumer retail.
💼 Employer●●●○○
Known for providing a stable, structured, and professional corporate environment characteristic of large multinational pharmaceutical entities.
📋 Mandate
As a stable pharma player, the firm requires pragmatic leadership focused on deepening the R&D pipeline and navigating complex regulatory environments.
🏢 Culture●●●●●
Global MNC subsidiary with deep focus on compliance, regulatory adherence, and standardized global processes typical of large pharma.
Financials
Revenue FY25₹2K Cr
PAT FY25₹116 Cr
Rev CAGR 5Y28.6%
OPM12.5%
NPM6.8%
ROE15%
ROCE26.4%
P/E104.2
Fwd P/E—
P/B26.3
D/E4.4
Promoter81.6%
Institutional7.1%
Mkt Cap₹22K Cr
Compensation
To Be Published
Data being verified from audited reports
